

What is claimed is:

1. A method of treating a condition associated with ocular neovascularization in a subject comprising administration of a peptide comprising the amino acid sequence of SEQ ID NO: 1.
- 5 2. A method of treating a condition associated with ocular neovascularization in a subject comprising administration of a peptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.
3. The method of claims 1 or 2, wherein said ocular neovascularization is  
10 choroidal neovascularization.
4. The method of claim 3, wherein said condition is age-related macular degeneration (AMD) or high myopia.
5. The method of claims 1 or 2, wherein said ocular neovascularization is retinal neovascularization.
- 15 6. The method of claim 5, wherein said condition is diabetic retinopathy, retinopathy of prematurity, or central vein occlusion.
7. The method of claims 1 or 2, wherein said ocular neovascularization is iris neovascularization.
8. The method of claim 7, wherein said condition is neovascular glaucoma.
- 20 9. The method of claims 1 or 2, wherein said peptide further comprises a modification.
10. The method of claim 9, wherein said modification is selected from the group consisting of addition of an antibody Fc and pegylation.

11. The method of claims 1 or 2, wherein said peptide comprises one or more D form amino acids.
12. The method of claim 1 or 2, wherein said peptide contains an N-terminal amide.
- 5 13. A method of treating cancer in a subject comprising administration of a peptide comprising the amino acid sequence of SEQ ID NO: 1.
14. A method of treating cancer in a subject comprising administration of a peptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.
- 10 15. The method of claims 13 or 14, wherein said cancer is breast cancer.
16. The method of claims 13 or 14, wherein said peptide further comprises a modification.
17. The method of claim 16, wherein said modification is selected from the group consisting of addition of an antibody Fc and pegylation.
- 15 18. The method of claims 13 or 14, wherein said peptide comprises one or more D form amino acids.
19. The method of claim 13 or 14, wherein said peptide contains an N-terminal amide.
20. A pharmaceutical composition comprising a peptide comprising the amino acid sequence of SEQ ID NO: 1.
- 20 21. A pharmaceutical composition comprising a peptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.

22. The pharmaceutical composition of claims 20 or 21, wherein said peptide further comprises a modification.
23. The pharmaceutical composition of claim 22, wherein said modification is selected from the group consisting of addition of an Fc antibody and pegylation.
- 5 24. The pharmaceutical composition of claims 20 or 21, wherein said peptide comprises one or more D form amino acids.
25. The pharmaceutical composition of claims 20 or 21, wherein said peptide contains an N-terminal amide.
26. A kit for the treatment of a condition associated with ocular neovascularization  
10 in a subject comprising (a) a composition comprising a peptide comprising the amino acid sequence of SEQ ID NO: 1 and (b) instructions for administration of said composition.
27. A kit for the treatment of a condition associated with ocular neovascularization in a subject comprising (a) a composition comprising a peptide with an amino acid  
15 sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5 and (b) instructions for administration of said composition.
28. A kit for the treatment of cancer in a subject comprising (a) a composition comprising a peptide comprising the amino acid sequence of SEQ ID NO: 1 and (b)  
20 instructions for administration of said composition.
29. A kit for the treatment of cancer in a subject comprising (a) a composition comprising a peptide with an amino acid sequence selected from the group

consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5 and  
(b) instructions for administration of said composition.